Finance

Lists
Why is MYGN down 2,55%?
Dive Deeper
MYGN:NASDAQ
Myriad Genetics Inc
4,20 USD
-2,55%
(-0,11) 1D
4,20 USD
0,00% (0,00)
After hours
Closed: 12-окт., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MYGN...
Open
4,30 USD
High
4,32 USD
Low
4,19 USD
Avg. vol.
2,04 млн
Volume
1,37 млн
52-wk high
8,59 USD
52-wk low
2,74 USD
EPS
-1,20 USD
Beta
1,64
Shares outstanding
95,65 млн
Open
4,30 USD
High
4,32 USD
Low
4,19 USD
Avg. vol.
2,04 млн
Volume
1,37 млн
52-wk high
8,59 USD
52-wk low
2,74 USD
EPS
-1,20 USD
Beta
1,64
Shares outstanding
95,65 млн
News stories
From web sources and news partners
About Myriad Genetics Inc
CEOPaul J. Diaz
Employees-
Founded1992
Headquarters-
Sector-
Websitemyriad.com
Analyst ratings
Based on 8 analysts giving stock ratings to MYGN in the past 3 months
Hold
Buy
1
Hold
4
Sell
3
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for MYGN in the last 3 months.
Highest
Current 4,20 USD
8,00 USD (+90,48%)
Average
3,76 USD (-10,48%)
Lowest
2,00 USD (-52,38%)
Analyst
Recommendation
Action
Price target
Projected
Date
William Bonello
Craig-Hallum
Buy
Maintained
8,00 USD
+90,5%
10/02/2026
Unknown Analyst
UBS
Hold
Initiated
3,60 USD
-14,3%
09/08/2026
Doug Schenkel
UBS
Hold
Maintained
3,60 USD
-14,3%
09/09/2026
David Westenberg
Piper Sandler
Sell
Downgraded
2,00 USD
-52,4%
09/01/2026
Unknown Analyst
Jefferies
Sell
Maintained
2,50 USD
-40,5%
08/21/2026
Mason Carrico
Stephens
Hold
Reiterated
3,00 USD
-28,6%
08/18/2026
Unknown Analyst
Guggenheim
Hold
Maintained
-
-
08/03/2026
Michael Ryskin
Bank of America Securities
Sell
Reiterated
3,20 USD
-23,8%
08/03/2026
Brandon Couillard
Wells Fargo
Hold
Maintained
3,00 USD
-28,6%
08/02/2026
Kyle Boucher
TD Cowen
Hold
Reiterated
4,00 USD
-4,8%
07/31/2026
Daniel Brennan
TD Cowen
Hold
Reiterated
4,00 USD
-4,8%
07/31/2026
Lu Li
UBS
Hold
Maintained
6,00 USD
+42,9%
02/25/2026
Previous reports
Loading Previous Earnings...
Revenue
Net income
Revenue
Cost of goods sold
Cost of revenue
Research and development expenses
Total research and development expenses
Selling, general, and admin expenses
Operating expense
Total operating expenses
Operating income
Other non operating income
EBT including unusual items
EBT excluding unusual items
Income tax expense
Effective tax rate
Other operating expenses
Net income
Net profit margin
Earnings per share
Interest and investment income
Interest expense
Net interest expenses
Depreciation and amortization charges
EBITDA
Gain or loss from assets sale
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору